We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Neurotoxicity, Neuroplasticity, and Magnetic Resonance Imaging Morphometry—Reply

Daniel R. Weinberger, MD; Robert K. McClure, MD
Arch Gen Psychiatry. 2003;60(8):848-849. doi:10.1001/archpsyc.60.8.846.
Text Size: A A A
Published online


In reply

In our article,1 we argued that changes in measurements on MRI scans over time in patients with schizophrenia should not be interpreted as evidence that neurodegeneration or neurotoxicity is a primary feature of the disease. The points that we raised to support this argument included the paucity of biologically plausible clinical-neuropathologic correlations, the remarkable inconsistency of the data, and the virtual absence of evidence of neurodegeneration in postmortem brain tissue, despite numerous studies. That Mathalon et al now state that concluding otherwise would be "misguided" suggests that our argument was convincing, as these authors in their earlier writings had advocated for a neurodegeneration interpretation (although their current use of the phrase "parenchyma lost" raises concerns that there is still some reluctance). In defending the MRI morphometry literature, they raise an important question: do longitudinal MRI morphometry studies contribute to our understanding of the brain disorder that accounts for the clinical condition? While our article addressed the problems with this literature in terms of a specific interpretation of the findings, we think that the question they now raise invites some additional comment.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...